GlaxoSmithKline Pharmaceuticals

GlaxoSmithKline Pharmaceuticals on Monday posted 29 per cent increase in consolidated profit after tax at Rs 296 crore for the third quarter ended December 31, 2025. The drugmaker reported a profit after tax of Rs 230 crore for the October-December period of last fiscal. Revenue from operations rose to Rs 1,041 crore from Rs 949 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals Ltd said in a regulatory filing. The company said its competitive performance comes against the backdrop of the broader macro environment and efforts to mitigate internal supply challenges. The implementation of the new Labour Codes did not have a material impact on the company, it added. Shares of the company on Monday settled 1.01 per cent up at Rs 2,511 apiece on BSE.

GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies for gynaecological cancers. The company has introduced advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in the country. "These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women's cancer care. With this launch, we are strengthening our long-term commitment to build the specialty medicine portfolio in India," GSK India MD Bhushan Akshikar said in a statement. Gynaecological cancers are among the most common cancers in women in India. By 2045, the incidence of endometrial and ovarian cancer in India is projected to increase by 78 per cent and 69 per cent, respectively. Endometrial cancer is a malignancy arising out of the endometrium, the inner lining of the uterus. Nearly a fourth of endometrial cancer patients in India are at an advanced stage where chemotherapy remains a standa

The up move in the GSK Pharma share price came after the company posted a healthy March quarter of financial year 2025 (Q4FY25) results.

Analysts believe that pharma shares continue to see buying interest, given the inelastic demand for medicines; tariffs, if any could have minimal impact on the industry.

GlaxoSmithKline Pharma stock has seen formation of 'Golden Cross' on the daily chart on Thursday; last time the stock saw a similar development, it rallied almost 117% over the next 14 months.

The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago

PVR Inox, Lodha, Glaxo, MRF and Astral are trading in oversold zone. Technical charts show these stocks can gain up to 33% from present level, or fall by another 19%; here's why.

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs 252 crore in the September quarter, aided by robust sales across segments. The drug maker posted a net profit of Rs 217 crore for the July-September quarter of last fiscal. Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. The company said its board declared a special interim dividend of Rs 12 per equity share of face value of Rs 10 each. "As we mark our centenary year in India, we are happy to announce a special interim dividend to our shareholders. Our performance reflects our commitment to sustainable growth and innovation," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The drugmaker said its key brands held their market share and continued to stay in line with the respective category performance. Augmentin ..

The brokerage has estimated a 9 per cent earnings growth over FY24-26 for GSK Pharma

The company had posted a consolidated net profit of Rs 132.25 crore in the same quarter last fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing

The board has recommended a dividend of Rs 32 per equity share on face value of Rs 10 each for the year ended 31 March 2024, subject to approval of members at 99th Annual General Meeting

Shingles is a painful rash caused by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Up to one in three people will develop shingles in their lifetime

GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of COVID-19

Even as the top pharmaceutical peers delivered a double digit growth in the December quarter, sales for GSK Pharma at Rs 805 crore was flat

GlaxoSmithKline Pharmaceuticals has also established an Omnichannel Team, leveraging technology to enhance its reach and coverage across target segments

GlaxoSmithKline Pharmaceuticals on Thursday said its board has approved a Voluntary Retirement Scheme (VRS) for a certain segment of employees under a strategic review of the business. In a regulatory filing, the drug firm said its board has approved a commercial transformation initiative as part of a strategic review of the business. "As part of the transformation and to continue to remain competitive, the company will explore new innovative solutions, including omnichannel strategy, to expand its reach and coverage to the target segments," the drug firm said. Further, the company has launched a voluntary retirement scheme for commercial function employees in field sales and head office. The initiative includes provisions for financial and transition support. The financial impact will be communicated separately, GlaxoSmithKline Pharmaceuticals said.

The top court was hearing a plea by a man challenging an order of the National Consumer Disputes Redressal Commission

GlaxoSmithKline Pharmaceuticals on Wednesday said its consolidated net profit increased by 11 per cent to Rs 132 crore for the first quarter ended June 30. The drug maker had reported a net profit of Rs 119 crore in the April-June quarter of the last fiscal. Its total income rose to Rs 798 crore in the first quarter against Rs 773 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "Despite the strong external headwinds, GSK remains focused on delivering best-in-class competitive performance and driving operational efficiencies. We remain committed to explore new growth opportunities and improving our leadership in key therapy areas," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. Shares of the company were trading 0.3 per cent down at Rs 1,399.20 apiece on the BSE.

GlaxoSmithKline Pharmaceuticals Ltd on Tuesday reported a 9.45 per cent rise in consolidated net profit at Rs 164.56 crore in the third quarter ended December 31, 2022. The company had posted a consolidated net profit of Rs 150.35 crore in the same quarter last fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing. Consolidated revenue from operations during the quarter under review stood at Rs 802.3 crore as against Rs 815.92 crore in the year-ago period, it added. Total expenses were lower at Rs 590.1 crore compared to Rs 636.56 crore in the corresponding quarter last fiscal. "General medicines portfolio grew by 10 per cent led by anti-infectives and dermatology therapies...Vaccine sales were down for the quarter in a declining self-pay vaccines market. However, we continue to gain market share for key vaccine brands," GSK Pharma Managing Director Bhushan Akshikar said. During the quarter, he said, the National List of Essential Medicines (NLEM), 2022

/ -- Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organisation (CRO-CDMO), today announced the joining of Stephen Hermitage (Steve) as Vice President, CMC. In this role Steve will join the global R&D leadership team at Sai Life Sciences, where he will add further deep scientific, process development and drug development experience to the R&D organisation. Making the announcement, Sauri Gudlavalleti, Chief Operating Officer said, "Over the past few years, our team has established a formidable reputation for itself as a high-quality scientific unit that can solve complex chemistry challenges. I am delighted to welcome Steve, a pharma industry veteran, onboard at Sai Life Sciences. His addition to our global delivery team further strengthens our ongoing efforts to build strong client partnerships and exceed client expectations by raising the bar on innovation, speed, and efficiency. Steve joins Sai Life Sciences from GlaxoSmithKline (GSK)